NCT01530490View on ClinicalTrials.gov

Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

August 31, 2008

Study Completion Date

September 30, 2010

Conditions
Complications Associated With Artificial FertilizationDisorder of Endocrine Ovary
Interventions
DRUG

Cabergoline and Hydroxyethyl Starch

0.5mg

DRUG

Hydroxyethyl Starch

0.5 mg cabergoline administration 8 days

All Listed Sponsors
lead

Hospital de Cruces

OTHER

NCT01530490 - Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention | Biotech Hunter | Biotech Hunter